Mentor Capital Inc. - Current Financials w/QI

Mentor Capital, Inc and CI Companies

66 Days Left on $1 Call

About Mentor Capital MNTR - QI Relationship About MNTR Summary Data Management Team Professional Support Philosophy Ethics Corporate Governance The Investor's Corner Current Financials w/QI 2008 Audit w/o QI 15(c) 2-11 Comparable Companies Analysts' Coverage $5 / Share - Sr. Securities Analyst $28 / Share by 2012, BioMed Reports Medical Trials & Publications FDA Trials Early Results Medical Publications Visit Portfolio Companies

Current Financials w/QI

All PDF Documents will open a new browser window

PDF Document Mentor Capital, Inc. Balance Sheet July 31, 2009

The Mentor Capital Cancer Immunotherapy Index^©

Our Science Explained

For Email Marketing you can trust

Site Search

Home

Chairman's Letters

◦ Welcome to the Team Leading the Cancer Fight

◦ Chairman's 2009 Recap with $0.91/sh Portfolio Gains

◦ List of All Releases

◦ MNTR Invests in 10 Cancer Index Companies

◦ MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund

◦ 2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR

◦ University Agreement Indicates Broad Cancer Application for QI Treatment

◦ New Lab, Filings and JV Talks

◦ MNTR Presents In NYC

◦ MNTR Leads Cancer Index

◦ Start of FDA Trials

◦ QI Announces MNTR

◦ MNTR Acquires First 20% of QI

◦ MNTR Calls $3 Million Tranche

◦ MNTR Initiates Trading

MNTR In The News

◦ All News Articles

◦ Mentor Capital Update in Seeking Alpha

◦ MNTR Top Gainer in Cancer Index

◦ MNTR Stealth Cancer Play

◦ MNTR Forecast at $28.60 in 2012

◦ Quantum Leap In Funding

Cancer Resources

Information For Brokers

Shareholder Updates

FAQ

All PDF documents will open a new browser window

©2009 Mentor Capital Inc. | All Rights Reserved

Safe Harbor Statement Site Map